PolyTherics and Minapharm Pharmaceuticals Sign Collaboration Agreement to Create Enhanced Biopharmaceuticals
PolyTherics Limited announced the initiation of a research collaboration agreement with Minapharm Pharmaceuticals. PolyTherics will apply its proprietary drug modification technologies to a target protein of commercial interest to Minapharm. Minapharm has an option to license the collaboration intellectual property for the development and commercialisation of novel products. Minapharm also receives an option to submit further target proteins of interest to future collaborations with PolyTherics.
PolyTherics receives an upfront licence fee and further payments on achievement of defined programme milestones. Details of the agreement terms were not disclosed.
Dr Keith Powell, Chief Executive Officer of PolyTherics, said: “Through multiple partnerships, we are uncovering the considerable development potential of our PEGylation technologies to create biotherapeutic product candidates. We are looking forward to collaborating with a company with such a solid reputation in innovative pharmaceuticals development as Minapharm.”
Other news from the department business & finance
